UkuLahla koBubunzima obuPhezulu kwiTirzepatide Unxibelelaniso kwizinto eziSixhenxe

Phakathi kwabantu abangama-3188 abanesifo sikashukela sohlobo lwe-2 ababebambelele kwirejimeni yabo ye-tirzepatide (i-Mounjaro, uLilly) kwiimvavanyo ezine ezibalulekileyo ze-arhente, ikota iphumelele ubuncinci i-15% yokusika kwi-baseline body weight after 40-42 iiveki zonyango, kwaye abaphandi bafumene iinguqu ezisixhenxe ezisisiseko eziye zadibaniswa kakhulu kunye nesiganeko esiphezulu sale nqanaba lokulahlekelwa kwesisindo.

"Ezi ziphumo zinceda ukwazisa ukuba ngabaphi abantu abanesifo seswekile se-2 abanokuthi bafikelele ekunciphiseni ubunzima bomzimba kunye nokuphuculwa kwezinto ezinobungozi be-cardiometabolic nge-tirzepatide," ababhali bathi.

ULWAZI-NKQUBO:

• Abaphandi baqhube uhlalutyo lwe-post hoc lwedatha eqokelelwe kwi-3188 yabantu abanesifo sikashukela sohlobo lwe-2 abaye babambelela kwirejimeni yabo eyabelwe i-tirzepatide kwiiveki ze-40-42 kuyo nayiphi na izilingo ezine ezibalulekileyo ze-arhente: SURPASS-1, SURPASS- 2, SURPASS-3, kunye ne-SURPASS-4.
• Abaphandi bajolise ekuchongeni izibikezelo zokunciphisa ubunzima bomzimba ubuncinane be-15% kunye nonyango lwe-tirzepatide kuyo nayiphi na imilinganiselo emithathu evavanyiweyo - 5 mg, 10 mg, okanye i-15 mg - eyayilawulwa nge-injection subcutaneous kanye ngeveki.
• Zonke izilingo ezine ezinikezela ngedatha zinqatshelwe unyango oluhambelanayo oluya kukhuthaza ukulahleka kwesisindo, kwaye abantu ababandakanyiweyo kuhlalutyo abazange bafumane nawaphi na amayeza okuhlangula ukulawula i-glycemia.
• Umlinganiselo ophambili wokuphumelela kuzo zonke izifundo ezine yayiyikhono le-tirzepatide ekuphuculeni ulawulo lwe-glycemic (ukulinganisa inqanaba le-A1c) xa kuthelekiswa ne-placebo, i-semaglutide (Ozempic) 1 mg SC kanye ngeveki, i-insulin degludec (Tresiba, Novo Nordisk), okanye i-insulin glargine ( Basaglar, Lilly).

YISE KUDE:

• Phakathi kwabantu be-3188 abahlala bebambelele kwirejimeni yabo ye-tirzepatide kwiiveki ze-40-42, i-792 (25%) yafumana ukunciphisa ubunzima ubuncinane be-15% ukusuka kwisiseko.
• Uhlalutyo lwe-multivariate lwe-covariates esisiseko lubonise ukuba ezi zinto zisixhenxe zinxulunyaniswa kakhulu ne-≥15% yokulahleka kwesisindo: idosi ephezulu ye-tirzepatide, ukuba ngowasetyhini, ukuba nguMhlophe okanye ubuhlanga baseAsia, ukuba mncinci ubudala, unyango nge-metformin, ukuba nolawulo olungcono lwe-glycemic. kwi-A1c esezantsi kunye ne-glucose ephantsi yokuzila ukutya kwiserum), kunye nokuba nenqanaba le-cholesterol ephantsi ye-non-high-density lipoprotein.
• Ngethuba lokulandelwa, ukufezekiswa ubuncinane kwe-15% yokunqunyulwa kwesiseko sobunzima bomzimba kwakudibaniswa kakhulu nokunciphisa okukhulu kwi-A1c, inqanaba le-glucose ye-serum yokuzila, umjikelezo wesinqe, uxinzelelo lwegazi, i-serum triglyceride level, kunye nenqanaba le-serum ye-enzyme yesibindi i-alanine transaminase. .
  

  IYASEBENZA:

  "Ezi ziphumo zinokuthi zibonelele ngolwazi oluxabisekileyo kwiikliniki nakubantu abanesifo seswekile esi-2 malunga nokuba nokwenzeka kokunciphisa ubunzima bomzimba nge-tirzepatide, kunye nokunceda ukubonakalisa uphuculo olunokuthi lubonwe kuluhlu lweeparamitha zengozi ye-cardiometabolic kunye nokulahlekelwa kwesisindo esibangelwa yi-tirzepatide. ,” baqukumbela ngelithi ababhali kwingxelo yabo.